VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
QLG2198
Phase 3
Small molecule
Q
Qilu Pharmaceutical (Hainan) Co., Ltd.
1
Indications
1
Total Trials
1
Active Trials
0
Competitors
Clinical
Trials by Indication
[1]
Pruritus
1 trial
Phase 3 Study of QLG2198 in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
Recruiting
·
Q
Qilu Pharmaceutical (Hainan) Co., Ltd.
·
Phase 3
·
NCT06446310
·
194 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for QLG2198. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
QLG2198 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for QLG2198. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
Qilu Pharmaceutical (Hainan) Co., Ltd. company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Phase 3
[1]
Company
Q
Qilu Pharmaceutical (Hainan) Co., Ltd.
Related News